SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
42.46 ^USD	-5.31%		+2.49%	+16.33%

May. 15	Transcript : SpringWorks Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:40 PM
May. 02	Wedbush Raises SpringWorks Therapeutics' Price Target to $75 From $70, Keeps Outperform Rating	MT

SpringWorks Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

November 03, 2022 at 06:35 am EDT

SpringWorks Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was USD 72.39 million compared to USD 41.04 million a year ago. Basic loss per share from continuing operations was USD 1.37 compared to USD 0.84 a year ago.
For the nine months, net loss was USD 203.24 million compared to USD 117.84 million a year ago. Basic loss per share from continuing operations was USD 4.04 compared to USD 2.43 a year ago.

Latest news about SpringWorks Therapeutics, Inc.

Transcript : SpringWorks Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:40 PM	May. 14
Wedbush Raises SpringWorks Therapeutics' Price Target to $75 From $70, Keeps Outperform Rating	May. 02	MT
SpringWorks Therapeutics Shares Fall After Wider-Than-Expected Q1 Loss	May. 02	MT
Transcript : SpringWorks Therapeutics, Inc., Q1 2024 Earnings Call, May 02, 2024	May. 02
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q1 Revenue $21M, vs. Street Est of $13.1M	May. 02	MT
SpringWorks Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Transcript : SpringWorks Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:00 AM	Mar. 12
JPMorgan Adjusts Price Target on SpringWorks Therapeutics to $75 From $74, Keeps Overweight Rating	Mar. 06	MT
HC Wainwright Raises Price Target on SpringWorks Therapeutics to $74 From $73, Maintains Buy Rating	Mar. 06	MT
SpringWorks Therapeutics Starts Rolling New Drug Application for Prospective Tumor Treatment	Mar. 04	MT
SpringWorks Therapeutics, Inc. Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN	Mar. 04	CI
SpringWorks Therapeutics Q4 Net Loss Widens; Full-Year Net Loss Narrows	Feb. 27	MT
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q4 Revenue $5.4M	Feb. 27	MT
Wedbush Raises SpringWorks Therapeutics' PT to $70 From $60, Increases Sales Estimates for Ogsiveo, Mirdametinib; Keeps Outperform Rating	Feb. 26	MT
Wedbush Raises SpringWorks Therapeutics' PT to $60 From $45 on Increased Valuation for Ogsiveo in Desmoid Tumors; Keeps Outperform Rating	Feb. 07	MT
Springworks Therapeutics Insider Sold Shares Worth $1,160,362, According to a Recent SEC Filing	Feb. 06	MT
SpringWorks Therapeutics, Inc. Announces Resignation of L. Mary Smith as Chief Development Officer	Feb. 02	CI
Barclays Adjusts Price Target on SpringWorks to $47 From $41, Keeps Overweight Rating	Jan. 25	MT
Transcript : SpringWorks Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 07:30 AM	Jan. 08
SpringWorks Therapeutics Closes $316.3 Million Common Stock Public Offering	Dec. 08	MT
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	Dec. 05	MT
Key Jobs Report Awaited as Exchange-Traded Funds, Equity Futures Decline Pre-Bell Tuesday	Dec. 05	MT
SpringWorks Therapeutics Prices $275 Million Share Offering	Dec. 05	MT
SpringWorks Therapeutics Launches $250 Million Public Offering of Shares; Stock Falls After Hours	Dec. 04	MT

Chart SpringWorks Therapeutics, Inc.

Duration

Period

More charts

Company Profile

SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. OGSIVEO (nirogacestat) is the Company's Food and Drug Administration (FDA)-approved therapy. OGSIVEO (nirogacestat) is approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The Company also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. Its ongoing developments include Nirogacestat for treatment of ovarian granulosa cell tumors, Nirogacestat in combination with B-cell maturation antigen (BCMA)-targeted agents, Mirdametinib Phase 2b ReNeu trial in NF1-PN and Brimarafenib (BGB-3245). The Company's early-stage pipeline includes SW-682, an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluated in Hippo-mutant solid tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-05-31 - American Society of Clinical Oncology Annual Meeting - Abstract Number : 11520

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for SpringWorks Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

42.46 USD

Average target price

67.36 USD

Spread / Average Target

+58.65%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SPRINGWORKS THERAPEUTICS, INC.	+16.33%	3.14B
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	107B
ARGENX SE	-3.38%	21.6B
BIONTECH SE	-12.38%	22.31B
GENMAB A/S	-5.29%	19.19B
BEIGENE, LTD.	-3.35%	18.23B
WUXI APPTEC CO., LTD.	-38.57%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.26B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.37B

Bio Therapeutic Drugs